Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19773434rdf:typepubmed:Citationlld:pubmed
pubmed-article:19773434lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:19773434lifeskim:mentionsumls-concept:C0128897lld:lifeskim
pubmed-article:19773434lifeskim:mentionsumls-concept:C0596263lld:lifeskim
pubmed-article:19773434lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:19773434lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:19773434lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:19773434pubmed:issue19lld:pubmed
pubmed-article:19773434pubmed:dateCreated2009-10-2lld:pubmed
pubmed-article:19773434pubmed:abstractTextAccumulating evidence indicates the crucial contribution of chronic inflammation to various types of carcinogenesis, including colon carcinoma associated with ulcerative colitis and asbestosis-induced malignant mesothelioma. Ulcerative colitis-associated colon carcinogenesis can be recapitulated in mice by azoxymethane administration followed by repetitive dextran sulfate sodium ingestion. In the course of this carcinogenesis process, the expression of a macrophage-tropic chemokine, CCL2, was enhanced together with intracolonic massive infiltration of macrophages, which were a major source of cyclooxygenase (COX)-2, a crucial mediator of colon carcinogenesis. Mice deficient in CCL2-specific receptor, CCR2, exhibited less macrophage infiltration and lower tumor numbers with attenuated COX-2 expression. Moreover, CCL2 antagonists decreased intracolonic macrophage infiltration and COX-2 expression, attenuated neovascularization, and eventually reduced the numbers and size of colon tumors, even when given after multiple colon tumors have developed. These observations identify CCL2 as a crucial mediator of the initiation and progression of chronic colitis-associated colon carcinogenesis and suggest that targeting CCL2 may be useful in treating colon cancers, particularly those associated with chronic inflammation.lld:pubmed
pubmed-article:19773434pubmed:languageenglld:pubmed
pubmed-article:19773434pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:citationSubsetIMlld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19773434pubmed:statusMEDLINElld:pubmed
pubmed-article:19773434pubmed:monthOctlld:pubmed
pubmed-article:19773434pubmed:issn1538-7445lld:pubmed
pubmed-article:19773434pubmed:authorpubmed-author:EgashiraKensu...lld:pubmed
pubmed-article:19773434pubmed:authorpubmed-author:WadaTakashiTlld:pubmed
pubmed-article:19773434pubmed:authorpubmed-author:FuruichiKengo...lld:pubmed
pubmed-article:19773434pubmed:authorpubmed-author:MukaidaNaofum...lld:pubmed
pubmed-article:19773434pubmed:authorpubmed-author:KondoToshikaz...lld:pubmed
pubmed-article:19773434pubmed:authorpubmed-author:PopivanovaBor...lld:pubmed
pubmed-article:19773434pubmed:authorpubmed-author:KostadinovaFe...lld:pubmed
pubmed-article:19773434pubmed:authorpubmed-author:ShamekhMohame...lld:pubmed
pubmed-article:19773434pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19773434pubmed:day1lld:pubmed
pubmed-article:19773434pubmed:volume69lld:pubmed
pubmed-article:19773434pubmed:ownerNLMlld:pubmed
pubmed-article:19773434pubmed:authorsCompleteYlld:pubmed
pubmed-article:19773434pubmed:pagination7884-92lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:meshHeadingpubmed-meshheading:19773434...lld:pubmed
pubmed-article:19773434pubmed:year2009lld:pubmed
pubmed-article:19773434pubmed:articleTitleBlockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice.lld:pubmed
pubmed-article:19773434pubmed:affiliationDivision of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.lld:pubmed
pubmed-article:19773434pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19773434pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19773434lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19773434lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19773434lld:pubmed